Perfluorohexyloctane Explained

Tradename:Miebo, others
Dailymedid:Perfluorohexyloctane
Routes Of Administration:Eye drops
Atc Prefix:None
Legal Ca:Rx-only
Legal Ca Comment:[1]
Legal Us:Rx-only
Legal Us Comment:[2]
Cas Number:133331-77-8
Pubchem:10477896
Drugbank:DB17823
Chemspiderid:8653305
Unii:7VYX4ELWQM
Kegg:D12604
Chebi:229658
Synonyms:NOV03; 1-(perfluorohexyl)octane
Iupac Name:1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane
C:14
H:17
F:13
Smiles:CCCCCCCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F
Stdinchi:1S/C14H17F13/c1-2-3-4-5-6-7-8-9(15,16)10(17,18)11(19,20)12(21,22)13(23,24)14(25,26)27/h2-8H2,1H3
Stdinchikey:WRYIIOKOQSICTB-UHFFFAOYSA-N

Perfluorohexyloctane, sold under the brand name Evotears among others, is a medication used for the treatment of dry eye disease. It is a semifluorinated alkane.

Perfluorohexyloctane has been available in multiple markets since 2015 under the brand names Evotears and Novatears,[3] and was additionally approved for medical use in the United States in May 2023 under the brand name Miebo.[4] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[5]

Medical uses

Perfluorohexyloctane is indicated for the treatment of the signs and symptoms of dry eye disease.[6] [7]

Society and culture

Economics

Perfluorohexyloctane when sold under the brand names Evotears or Novatears is available in multiple countries over-the-counter[8] costing NZ$34.00, A$30, and €30 for approximately a one-month supply. When sold in the US under the brand Miebo a prescription is required.

Further reading

Notes and References

  1. Web site: Notice: Multiple additions to the Prescription Drug List (PDL) [2024-10-18] ]. . 18 October 2024 . 25 October 2024.
  2. Web site: Miebo- perfluorohexyloctane solution . DailyMed . 18 May 2023 . 8 June 2023.
  3. URSAPHARM GmbH and Novaliq GmbH Announce European Partnership Agreement . 2024-02-15.
  4. Bausch + Lomb and Novaliq Announce FDA Approval of Miebo (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease . Bausch + Lomb Corporation . Business Wire . 18 May 2023 . 8 June 2023.
  5. New Drug Therapy Approvals 2023 . U.S. Food and Drug Administration (FDA) . January 2024 . PDF . 9 January 2024 . https://web.archive.org/web/20240110032419/https://www.fda.gov/media/175253/download . 10 January 2024 . live .
  6. Ballesteros-Sánchez A, De-Hita-Cantalejo C, Sánchez-González MC, Jansone-Langine Z, de Sotomayor MA, Culig J, Sánchez-González JM . Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent . The Ocular Surface . 30 . 254–262 . October 2023 . 37813152 . 10.1016/j.jtos.2023.10.001 . 11441/151762 . 263802332 . free .
  7. Sheppard JD, Evans DG, Protzko EE . A review of the first anti-evaporative prescription treatment for dry eye disease: perfluorohexyloctane ophthalmic solution . The American Journal of Managed Care . 29 . 14 Suppl . S251–S259 . November 2023 . 37930231 . 10.37765/ajmc.2023.89464 . 265032840 . free .
  8. In Australia, NovaTears Eye Drops Are Available on the Pharmaceutical Benefits Scheme (PBS) from Now On . 2024-02-15.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Perfluorohexyloctane".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.